ストックスクリーナーアプリを入手
12.57
21.10%
2.19
アフターアワーズ：
12.74
0.17
+1.35%
Syndax Pharmaceuticals Inc (SNDX) 最新ニュース
Syndax Pharmaceuticals Faces Ongoing and Emerging Business Risks: A Closer Look at SEC Filings - TipRanks
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Syndax Pharmaceuticals’ Earnings Call Highlights Robust Growth - TipRanks
Syndax Pharmaceuticals (NASDAQ:SNDX) Posts Earnings Results, Beats Estimates By $0.18 EPS - MarketBeat
Evaluating the High-Growth Potential of Biopharma Innovators in 2025: A Deep Dive into Day One, Beam Therapeutics, and Syndax Pharmaceuticals - AInvest
Syndax Pharmaceuticals (SNDX) Surges on Strong Q2 2025 Results - GuruFocus
Syndax stock up as Citi issues catalyst watch (SNDX:NASDAQ) - Seeking Alpha
Syndax Stock (SNDX) Moves Higher: Analysts Raise PTs on Strong Revenue, Approaching Catalyst - AskTraders.com
Syndax Pharmaceuticals: The Story Brightens (NASDAQ:SNDX) - Seeking Alpha
Citi ups Syndax target, opens ‘upside catalyst watch’ - TipRanks
Syndax stock price target raised to $20 from $18 at Goldman Sachs - Investing.com Canada
Health Check: How Prudently Does Syndax Pharmaceuticals (NASDAQ:SNDX) Use Debt? - simplywall.st
Syndax Pharmaceuticals Shares Soar 12.62% on Strong Q2 Earnings - AInvest
Syndax: Q2 Earnings Snapshot - New Haven Register
Syndax Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Syndax Pharmaceuticals' Q2 2025: Unpacking Key Contradictions in Revuforj's Impact on Patient Care and Market Growth - AInvest
Syndax Pharmaceuticals Wins Over Wall Street With Strong Drug Gains - Finimize
Syndax Reports Losses, But Wall Street Still Sees Big Upside - Finimize
Syndax Pharmaceuticals: Navigating the Path to Profitability with Two Blockbuster Candidates - AInvest
Syndax Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Syndax Pharmaceuticals Q2 2025 beats forecasts, stock rises - Investing.com Canada
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Syndax Pharmaceuticals earnings beat by $0.18, revenue topped estimates - Investing.com UK
Syndax Q2 2025 presentation: Strong revenue growth despite widening losses - Investing.com Canada
SNDX Surpasses Revenue Expectations with Strong Product Sales - GuruFocus
Syndax Pharmaceuticals Inc SEC 10-Q Report - TradingView
Syndax Reports 43% Revuforj Growth, $28.6mln Net Revenue in Q2. - AInvest
Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Press Release: Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update - 富途牛牛
XTX Topco Ltd Invests $783,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
What are the latest earnings results for Syndax Pharmaceuticals Inc.Unlock powerful investment tools for free - Jammu Links News
What is the risk reward ratio of investing in Syndax Pharmaceuticals Inc. stockAchieve rapid portfolio growth with expert guidance - Jammu Links News
How does Syndax Pharmaceuticals Inc. generate profit in a changing economyDiscover breakthrough investment opportunities - Jammu Links News
What institutional investors are buying Syndax Pharmaceuticals Inc. stockBuild a diversified portfolio for steady profits - Jammu Links News
How strong is Syndax Pharmaceuticals Inc. company’s balance sheetUnlock steady growth with low-risk stocks - Jammu Links News
Published on: 2025-08-03 12:28:04 - Jammu Links News
How many analysts rate Syndax Pharmaceuticals Inc. as a “Buy”Discover stocks with explosive growth potential - Jammu Links News
Why is Syndax Pharmaceuticals Inc. stock attracting strong analyst attentionTrack stocks with high upside potential easily - Jammu Links News
What is the dividend policy of Syndax Pharmaceuticals Inc. stockAchieve unparalleled market performance - Jammu Links News
What is Syndax Pharmaceuticals Inc. company’s growth strategyUnstoppable profit momentum - Jammu Links News
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 6.2%Still a Buy? - MarketBeat
Syndax Pharmaceuticals's Earnings: A Preview - 富途牛牛
GSA Capital Partners LLP Buys 50,427 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals Inc to Host Earnings Call - ACCESS Newswire
Syndax Pharmaceuticals (SNDX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
What’s the recovery path for long term holders of Syndax Pharmaceuticals Inc.Low Capital High Return Stock Plans Reviewed - metal.it
Screener Results Flag Syndax Pharmaceuticals Inc. as OversoldConservative Entry for High Return Setup Backed - beatles.ru
All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy - Yahoo Finance
Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know - sharewise.com
Bollinger Bands Show Potential Breakout in Syndax Pharmaceuticals Inc.Smart Trade Plans With Risk Protection Explained - metal.it
Published on: 2025-07-29 05:21:51 - metal.it
Recovery Setup Building in Syndax Pharmaceuticals Inc. Experts SayReal-Time Market Sentiment Tracking Gains Momentum - metal.it
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025 - GlobeNewswire
0.40%
0.08%
大文字化:
|
ボリューム (24 時間):